Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics
- 18 May 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 14 (3), 554-558
- https://doi.org/10.1208/s12248-012-9369-y
Abstract
Monoclonal antibodies are increasingly being developed to treat multiple disease areas, including those related to oncology, immunology, neurology, and ophthalmology. There are multiple factors, such as charge, size, neonatal Fc receptor (FcRn) binding affinity, target affinity and biology, immunoglobulin G (IgG) subclass, degree and type of glycosylation, injection route, and injection site, that could affect the pharmacokinetics (PK) of these large macromolecular therapeutics, which in turn could have ramifications on their efficacy and safety. This minireview examines how characteristics of the antibodies could be altered to change their PK profiles. For example, it was observed that a net charge modification of at least a 1-unit shift in isoelectric point altered antibody clearance. Antibodies with enhanced affinity for FcRn at pH 6.0 display longer serum half-lives and slower clearances than wild type. Antibody fragments have different clearance rates and tissue distribution profiles than full length antibodies. Fc glycosylation is perceived to have a minimal effect on PK while that of terminal high mannose remains unclear. More investigation is warranted to determine if injection route and/or site impacts PK. Nonetheless, a better understanding of the effects of all these variations may allow for the better design of antibody therapeutics.Keywords
This publication has 40 references indexed in Scilit:
- Quantitative Prediction of Human Pharmacokinetics for Monoclonal AntibodiesClinical Pharmacokinetics, 2011
- Effects of Charge on Antibody Tissue Distribution and PharmacokineticsBioconjugate Chemistry, 2010
- Charge variants in IgG1mAbs, 2010
- Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus MonkeysDrug Metabolism and Disposition, 2010
- Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and DiseaseThe AAPS Journal, 2009
- CNS Delivery Via Adsorptive TranscytosisThe AAPS Journal, 2008
- Factors determining antibody distribution in tumorsTrends in Pharmacological Sciences, 2008
- Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in miceBiologicals, 2008
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Elimination mechanisms of therapeutic monoclonal antibodiesDrug Discovery Today, 2006